Ponazuril: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 07:09, 23 October 2024 edit76.174.0.57 (talk) Add TrkA and TrkB PAM activity.← Previous edit		Latest revision as of 03:18, 7 December 2024 edit undoGettinglit (talk \| contribs)Extended confirmed users1,005 edits The ® isn't needed
Line 52:		Line 52:
	}}		}}

	'''Ponazuril''' (]), sold by Merial, Inc.,<ref>{{Cite web\|url=http://merial.com/en/content-pages/press-releases/merial-acquires-two-major-equine-health-products-from-bayer\|title=Merial Acquires LEGEND® and MARQUIS® \| work = Boehringer Ingelheim \|access-date=2018-04-30}}</ref> now part of ],<ref>{{Cite web\|url=https://www.boehringer-ingelheim.com/press-release/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017\|title=Sanofi and Boehringer Ingelheim confirm Closing of business swap {{!}} www.boehringer-ingelheim.com\|website=boehringer-ingelheim.com\|language=en\|access-date=2018-04-30}}</ref> under the trade name '''Marquis® (15% w/w ponazuril)''', is a drug currently approved for the treatment of ] (EPM) in horses, caused by ] '']''.<ref>{{cite web \| title = Marquis \| url = https://www.drugs.com/pro/marquis.html \| work = Drugs.com}}</ref><ref>{{cite journal \| vauthors = Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ \| title = Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses \| journal = American Journal of Veterinary Research \| volume = 69 \| issue = 3 \| pages = 396–402 \| date = March 2008 \| pmid = 18312139 \| doi = 10.2460/ajvr.69.3.396 \| doi-access = free }}</ref> Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.{{cn\|date=December 2022}} Along with its ] ], ponazuril (also known as ACD855) is a ] of the ]s ] and ].<ref name="DahlströmMadjidNordvall2021">{{cite journal \| vauthors = Dahlström M, Madjid N, Nordvall G, Halldin MM, Vazquez-Juarez E, Lindskog M, Sandin J, Winblad B, Eriksdotter M, Forsell P \| title = Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction \| journal = Cells \| volume = 10 \| issue = 8 \| date = July 2021 \| page = 1871 \| pmid = 34440640 \| pmc = 8391421 \| doi = 10.3390/cells10081871 \| doi-access = free \| url = }}</ref>		'''Ponazuril''' (]), sold by Merial, Inc.,<ref>{{Cite web\|url=http://merial.com/en/content-pages/press-releases/merial-acquires-two-major-equine-health-products-from-bayer\|title=Merial Acquires LEGEND® and MARQUIS® \| work = Boehringer Ingelheim \|access-date=2018-04-30}}</ref> now part of ],<ref>{{Cite web\|url=https://www.boehringer-ingelheim.com/press-release/sanofi-and-boehringer-ingelheim-confirm-closing-business-swap-january-1st-2017\|title=Sanofi and Boehringer Ingelheim confirm Closing of business swap {{!}} www.boehringer-ingelheim.com\|website=boehringer-ingelheim.com\|language=en\|access-date=2018-04-30}}</ref> under the trade name '''Marquis (15% w/w ponazuril)''', is a drug currently approved for the treatment of ] (EPM) in horses, caused by ] '']''.<ref>{{cite web \| title = Marquis \| url = https://www.drugs.com/pro/marquis.html \| work = Drugs.com}}</ref><ref>{{cite journal \| vauthors = Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ \| title = Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses \| journal = American Journal of Veterinary Research \| volume = 69 \| issue = 3 \| pages = 396–402 \| date = March 2008 \| pmid = 18312139 \| doi = 10.2460/ajvr.69.3.396 \| doi-access = free }}</ref> Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.{{cn\|date=December 2022}} Along with its ] ], ponazuril (also known as ACD855) is a ] of the ]s ] and ].<ref name="DahlströmMadjidNordvall2021">{{cite journal \| vauthors = Dahlström M, Madjid N, Nordvall G, Halldin MM, Vazquez-Juarez E, Lindskog M, Sandin J, Winblad B, Eriksdotter M, Forsell P \| title = Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction \| journal = Cells \| volume = 10 \| issue = 8 \| date = July 2021 \| page = 1871 \| pmid = 34440640 \| pmc = 8391421 \| doi = 10.3390/cells10081871 \| doi-access = free \| url = }}</ref>

	== See also ==		== See also ==

Latest revision as of 03:18, 7 December 2024

Chemical compound Pharmaceutical compound

Ponazuril
Clinical data

Trade names	Marquis
Other names	ACD855; ACD-855
AHFS/Drugs.com	FDA Professional Drug Information
Routes of administration	Oral
ATCvet code	QP51BC04 (WHO)
Legal status
Legal status	US: ℞-only Veterinary use only
Identifiers
IUPAC name 1-Methyl-3-phenyl]-1,3,5-triazinane-2,4,6-trione
CAS Number	69004-04-2
PubChem CID	3050408
ChemSpider	2312474
UNII	JPW84AS66U
CompTox Dashboard (EPA)	DTXSID7048958
ECHA InfoCard	100.157.907
Chemical and physical data
Formula	C₁₈H₁₄F₃N₃O₆S
Molar mass	457.38 g·mol
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)S(=O)(=O)C(F)(F)F
InChI InChI=1S/C18H14F3N3O6S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)30-12-4-6-13(7-5-12)31(28,29)18(19,20)21/h3-9H,1-2H3,(H,22,25,26) Key:VBUNOIXRZNJNAD-UHFFFAOYSA-N
(what is this?) (verify)

Ponazuril (INN), sold by Merial, Inc., now part of Boehringer Ingelheim, under the trade name Marquis (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona. Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM. Along with its analogue ACD856, ponazuril (also known as ACD855) is a positive allosteric modulator of the tropomyosin receptor kinases TrkA and TrkB.

References

"Merial Acquires LEGEND® and MARQUIS®". Boehringer Ingelheim. Retrieved 2018-04-30.
"Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.
"Marquis". Drugs.com.
Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ (March 2008). "Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.
Dahlström M, Madjid N, Nordvall G, Halldin MM, Vazquez-Juarez E, Lindskog M, Sandin J, Winblad B, Eriksdotter M, Forsell P (July 2021). "Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction". Cells. 10 (8): 1871. doi:10.3390/cells10081871. PMC 8391421. PMID 34440640.

Growth factor receptor modulators

Angiopoietin

Agonists: Angiopoietin 1
Angiopoietin 4

Antagonists: Angiopoietin 2
Angiopoietin 3

Kinase inhibitors: Altiratinib
CE-245677
Rebastinib

Antibodies: Evinacumab (against angiopoietin 3)
Nesvacumab (against angiopoietin 2)

CNTF

Agonists: Axokine
CNTF
Dapiclermin

EGF (ErbB)

EGF (ErbB1/HER1)	Agonists: Amphiregulin Betacellulin EGF (urogastrone) Epigen Epiregulin Heparin-binding EGF-like growth factor (HB-EGF) Murodermin Nepidermin Transforming growth factor alpha (TGFα) Kinase inhibitors: Afatinib Agerafenib Brigatinib Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab mafodotin Futuximab Imgatuzumab Matuzumab Necitumumab Nimotuzumab Panitumumab Zalutumumab
ErbB2/HER2	Agonists: Unknown/none Antibodies: Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab emtansine Kinase inhibitors: Afatinib Lapatinib Mubritinib Neratinib Tucatinib
ErbB3/HER3	Agonists: Neuregulins (heregulins) (1, 2, 6 (neuroglycan C)) Antibodies: Duligotumab Patritumab Seribantumab
ErbB4/HER4	Agonists: Betacellulin Epigen Heparin-binding EGF-like growth factor (HB-EGF) Neuregulins (heregulins) (1, 2, 3, 4, 5 (tomoregulin, TMEFF))

FGF

FGFR1	Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20) Repifermin Selpercatinib Trafermin Velafermin
FGFR2	Agonists: Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 7 (KGF), 8, 9, 10 (KGF2), 17, 18, 22) Palifermin Repifermin Selpercatinib Sprifermin Trafermin Antibodies: Aprutumab Aprutumab ixadotin Kinase inhibitors: Infigratinib
FGFR3	Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 8, 9, 18, 23) Selpercatinib Sprifermin Trafermin Antibodies: Burosumab (against FGF23)
FGFR4	Agonists: Ersofermin FGF (1, 2 (bFGF), 4, 6, 8, 9, 19) Trafermin
Unsorted	Agonists: FGF15/19

HGF (c-Met)

Agonists: Fosgonimeton
Hepatocyte growth factor

Potentiators: Dihexa (PNB-0408)

IGF

IGF-1

IGF-2

Agonists: Insulin-like growth factor-2 (somatomedin A)

Antibodies: Dusigitumab
Xentuzumab (against IGF-1 and IGF-2)

Others

Binding proteins: IGFBP (1, 2, 3, 4, 5, 6, 7)

Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
Trofinetide

LNGF (p75)

Antibodies: Against NGF: ABT-110 (PG110)
ASP-6294
Fasinumab
Frunevetmab
Fulranumab
MEDI-578
Ranevetmab
Tanezumab

Aptamers: Against NGF: RBM-004

Decoy receptors: LEVI-04 (p75-Fc)

PDGF

Agonists: Becaplermin
Platelet-derived growth factor (A, B, C, D)

RET (GFL)

GFRα1	Agonists: Glial cell line-derived neurotrophic factor (GDNF) Liatermin Kinase inhibitors: Vandetanib
GFRα2	Agonists: Neurturin (NRTN) Kinase inhibitors: Vandetanib
GFRα3	Agonists: Artemin (ARTN) Kinase inhibitors: Vandetanib
GFRα4	Agonists: Persephin (PSPN) Kinase inhibitors: Vandetanib
Unsorted	Kinase inhibitors: Agerafenib